Adalimumab Modulates Angiogenesis in Psoriatic Skin
| Autor: | A. Campanati, G. Moroncini, G. Ganzetti, K.N. Pozniak, G. Goteri, A. Giuliano, E. Martina, G. Liberati, F. Ricotti, A. Gabrielli, A. Offidani |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: | |
| Zdroj: | European Journal of Inflammation, Vol 11 (2013) |
| Druh dokumentu: | article |
| ISSN: | 1721-727X 1721727X |
| DOI: | 10.1177/1721727X1301100218 |
| Popis: | Angiogenesis plays a key role in the pathogenesis of psoriasis. New blood vessel formation occurs early during plaque lesion development in psoriatic skin, and sometimes precedes disease recurrence. TNF-α, a well established mediator of inflammation in psoriasis, up-regulates the transcription of several pro-angiogenic chemokines that are over-expressed in psoriatic skin and serum, promoting microvascular modifications in psoriatic plaque. Adalimumab is a fully human monoclonal antibody that blocks the interaction between TNF-α and its cell surface receptor, thus inhibiting the TNF-α dependent inflammatory cascade. The aims of this study were to investigate several angiogenic parameters involved in the pathogenesis of psoriasis, and to evaluate the ability of adalimumab to modulate them. Fifteen patients affected by psoriasis received Adalimumab 40 mg EOW for twelve weeks and were evaluated at baseline (T 0 ) and after treatment (T 12 ) for the following parameters: i) new blood vessels formation in lesional skin assessed by intra-vital video-capillaroscopy analysis (IVCP) and histology; ii) VEGF and Factor VIII expression in lesional skin detected by immunohistochemistry; iii) serological levels of several angiogenic chemokines detected by luminex assay. At baseline, newly formed capillaries in psoriatic plaque correlated with skin expression of VEGF and factor VIII and with serum levels of angiopoietin-2, IL-8, PDGF-BB, VEGF, but not with serum levels of follistatin, TNF-α, G-CSF, HGF, FGF, PECAM, IFN-γ, and TGF-α. All patients responded to adalimumab, reached PASI 50, and 70% achieved PASI 75 after twelve weeks of treatment. Although adalimumab administration for twelve weeks caused a dramatic decrease of new blood vessel formation, confirmed by IVCP (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|